Brentuximab vedotin treatment for mycosis fungoides with CD30+ large‐cell transformation in the early stage
In this paper, we bring hope to patients with mycosis fungoides (MF) with CD30+ large‐cell transformation (LCT), which is often a histological marker of poor prognosis and is associated with a mean 5‐year survival of <20%. Although skin biopsy is a painful procedure, it is the only test for early di...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2023-12-01
|
| Серія: | Journal of Cutaneous Immunology and Allergy |
| Онлайн доступ: | https://doi.org/10.1002/cia2.12330 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|